|
|
Blood, 1 February 2007, Vol. 109, No. 3, pp. 1061-1068.
Prepublished online as a Blood First Edition Paper on September 28, 2006; DOI 10.1182/blood-2006-05-023556.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover
Selinda J. Orr1,
Nuala M. Morgan1,
Joanne Elliott1,
James F. Burrows1,
Christopher J. Scott2,
Daniel W. McVicar3, and
James A. Johnston1
1 Infection and Immunity, Centre for Cancer Research and Cell Biology, Queens University, Belfast, United Kingdom;
2 Molecular Therapeutics, School of Pharmacy, Queens University, Belfast, United Kingdom;
3 Laboratory of Experimental Immunology, Division of Basic Sciences, National Cancer Institute–Frederick Cancer Research and Development Center, (NCI-FCRDC), Frederick, MD
CD33 is a member of the sialic acid–binding immunoglobulin-like lectin (Siglec) family of inhibitory receptors and a therapeutic target for acute myeloid leukemia (AML). CD33 contains a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM), which can recruit SHP-1 and SHP-2. How CD33 expression is regulated is unclear. Suppressor of cytokine signaling 3 (SOCS3) is expressed in response to cytokines, LPS, and other PAMPs, and competes with SHP-1/2 binding to ITIMs of cytokine receptors, thereby inhibiting signaling. In this study, using peptide pull-down experiments, we found that SOCS3 can specifically bind to the phosphorylated ITIM of CD33. Additionally, following cross-linking SOCS3 can recruit the ECS E3 ligase resulting in accelerated proteasomal degradation of both CD33 and SOCS3. Our data suggest that the tyrosine motifs in CD33 are not important for internalization, while they are required for degradation. Moreover, SOCS3 inhibited the CD33-induced block on cytokine-induced proliferation. This is the first receptor shown to be degraded by SOCS3 and where SOCS3 and its target protein are degraded concomitantly. Our findings clearly suggest that during an inflammatory response, the inhibitory receptor CD33 is lost by this mechanism. Moreover, this has important clinical implications as tumors expressing SOCS3 may be refractory to  -CD33 therapy.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Pairing SOCS with CD33
- Edward D. Ball
Blood 2007 109: 852.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
M. Yoshizaki, A. Tazawa, E. Kasumi, S. Sasawatari, K. Itoh, T. Dohi, T. Sasazuki, K. Inaba, A. P. Makrigiannis, and N. Toyama-Sorimachi
Spatiotemporal regulation of intracellular trafficking of Toll-like receptor 9 by an inhibitory receptor, Ly49Q
Blood,
August 20, 2009;
114(8):
1518 - 1527.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. D. Winn, M. Gormley, A. C. Paquet, K. Kjaer-Sorensen, A. Kramer, K. K. Rumer, R. Haimov-Kochman, R.-F. Yeh, M. T. Overgaard, A. Varki, et al.
Severe Preeclampsia-Related Changes in Gene Expression at the Maternal-Fetal Interface Include Sialic Acid-Binding Immunoglobulin-Like Lectin-6 and Pappalysin-2
Endocrinology,
January 1, 2009;
150(1):
452 - 462.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. Orabona, M. T. Pallotta, C. Volpi, F. Fallarino, C. Vacca, R. Bianchi, M. L. Belladonna, M. C. Fioretti, U. Grohmann, and P. Puccetti
SOCS3 drives proteasomal degradation of indoleamine 2,3-dioxygenase (IDO) and antagonizes IDO-dependent tolerogenesis
PNAS,
December 30, 2008;
105(52):
20828 - 20833.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. Masuhiro, K. Kayama, A. Fukushima, K. Baba, M. Soutsu, Y. Kamiya, M. Gotoh, N. Yamaguchi, and S. Hanazawa
SOCS-3 Inhibits E2F/DP-1 Transcriptional Activity and Cell Cycle Progression via Interaction with DP-1
J. Biol. Chem.,
November 14, 2008;
283(46):
31575 - 31583.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Elliott
SOCS3 in Liver Regeneration and Hepatocarcinoma
Mol. Interv.,
February 1, 2008;
8(1):
19 - 21.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
